Sugi Predict
/ Targets
/ PARP1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PARP1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients |
PHASE3 | COMPLETED |
| Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments |
PHASE3 | COMPLETED |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy |
PHASE1/PHASE2 | UNKNOWN |
| Olaparib In Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations |
PHASE1/PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure |
PHASE2 | UNKNOWN |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer |
PHASE1 | UNKNOWN |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Pre-Operative Radiation and Veliparib for Breast Cancer |
PHASE1 | COMPLETED |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors |
PHASE1 | COMPLETED |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
PHASE1 | WITHDRAWN |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer |
PHASE1 | COMPLETED |
| A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
PHASE1 | ACTIVE_NOT_RECRUITING |
| PET Imaging of PARP Activity in Cancer |
EARLY_PHASE1 | UNKNOWN |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
nan | NO_LONGER_AVAILABLE |
| Sirtuin1 in COVID19 Patients |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a PARP1 binder may also engage these)